Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Completely incorrect but that's OK. Couch is correct.
I hope ALO02 gets approved. That helps actually. Got to love it when you prove Elite has the same tech as Pfizer which we already knew and will also get approved. You do realize that is the argument you are making....truly lol
Lasers, based on the previous patent and reasons for allowance, you should see notice of allowance next week. 5 business days.
You need to read what I just wrote. What you are saying makes no sense. You do realize that the Chairman just bought six million shares. That is six hundred thousand dollars of his own personal money. You think he doesn't know "what is coming"?
That is why the deal with Epic was so attractive. They are picking up all the costs associated with the products. So it is straight revenue. Many of the products have one or two competitors. You can find out more about them because they were in the Actavis / Watson divestiture agreement. The first product only has one competitor and they expect it rather quickly.
Epic has tons of shares and they have to get the liquidity to get these products to market. They will make much more by meeting their obligations to Elite and getting Elite the revenue to cover all the R&D.
Anyone complaining should listened to the CC or doesn't understand that this eliminates a certain amount of dilution. Elite has to get the cash from somewhere and Epic picking up the product cost and giving Elite the best deal makes the most sense for shareholders....which Epic is the largest one...
Elite could sell shares to LPC for funds better used for trials on billion dollar products or Epic can sell 1-2% of their holdings now and then and give Elite straight profit. It is kind of a no brainer. Folks at Epic are going to be stupid rich but you still have to pay the bills first.
Based on the information I have read here actually, it would seem that this deal is simply suspended and going to happen shortly. He should address it and I suspect he is about to.
Long term, short term. Will we see results in a few weeks? Then the next drug enters studies. We don't even know what it is yet but it is probably one that is not even abuse resistant on the market, maybe not even in development elsewhere. Do folks realize we have been negotiating with multiple major pharmaceutical companies on multiple products and studies? I am talking about the largest drug companies in the world.
This is likely well in excess of $3 billion dollars in products in development headed to studies based on the recent news and developments. The twice daily is noted as $2.7B by itself
What is also funny is there are multiple drug approvals and drug transfers pending. Have you ever seen a company like this at this kind of market cap? Chairman just bought six million shares himself. That was six hundred thousand dollars....He already had a couple million shares.
Just a great day for Elite investors. It is an exciting time
Clark is IPTV. Not sure people fully get that. He can do whatever he wants with it.
I see the bloom is off the rose a bit here. Too bad. I suspect we will see a new IPTV deal and we will run again. You do have to wonder about the bigger picture and what is really going on though. It sure is a strange one. Most fascinating.
If it doesn't matter, then let's see if you can come up with the same 5 I have concluded. One is tricky but obvious if you have been paying attention.
That would be a good question for the CC> I suspect the milestone payment may be more then $200k. Not sure if they will give it out though
These new products are really good product. Some have only one or two competitors in the marketplace. The deal with Epic will only drive lots of profit.
Only two types of fretting can be seen over this Q report
One is if you sold your shares
Two is if you wish you bought more shares.
Great report and it really lays the groundwork for rapidly increasing revenues not even counting the ART. They are growing two businesses in essence.
You clearly just noted that the derivative accounting and rise in PPS was a big problem and then you said it was to show that other people would see the reverse as a positive and now you say there was no misinformation? Seriously you are again presenting misinformation about misinformation...ironic I believe and I do love irony.
Poorme,
Do you have any idea how many ART products Elite is eyeing right now? Right now I think the number is five. How many can you name?
ELTP is in one heck of a great position right now. Better then much of the competition because they are about to be completely self sufficient over the next year not counting ART. That puts them in better position then most of their competition.
Also we know there are partners interested so you are really on the precipice of great things.
Huh? Great revenue, great forward looking statements, Great CC coming and you think the stock is going to tank? Obviously the stock is going up tomorrow.
You can disregard anything you want. What you or others do means little to me so I am not sure I understand your reply. You can call and ask the CEO yourself on Monday if you want.
Brilliant Quarter and another brilliant CC coming up on Monday.
You have to read the 10k and the press releases and then think a little outside the box and do a little math. Good luck.
Thanks Ryan. CC is going to be awesome. I have no doubt. So many questions though.
Is it just Oxy?
Update on once daily in Europe?
Lodrane 24 replacement update
Patents pending
Next drug launches
Next Drug approvals
Some simple math tells you this is already a profitable drug company and rapidly growing pipeline and revenues if you take away the ART program. Of course you would never do that because that is billions but it is impressive nonetheless.
A couple more notes about the filing
83% increase YOY
They now have a ton of cash to move forward. It would seem to be for several trials, or several products actually
CC on Monday should be huge
$1.9m in inventory. Between the MS payment and this, I believe you are looking at a $2m quarter next quarter and rapidly growing
http://online.wsj.com/article/PR-CO-20131114-913833.html?dsk=y
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2014
Revenues Increase by 83%, Product Development Accelerating
Conference Call Scheduled for Monday, November 18 at 3:00 PM ET
NORTHVALE, N.J., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the second quarter of fiscal year 2014 ended September 30, 2013.
Total revenues for the quarter ended September 30, 2013 were $1.2 million, an increase of 83% from the prior year. This growth is attributed to the recent launch of 3 new products, Naltrexone 50mg in the September quarter and Phentermine 15mg and 30mg capsules in the June quarter, combined with strong year-on-year growth of Elite's Phentermine 37.5mg tablets, Hydromorphone 8mg tablets and contract manufactured Methadone 10mg product lines.
Consolidated quarterly loss from operations was $0.7 million, and GAAP net income, including non-cash income related to the accounting treatment of preferred share and warrant derivatives was a net loss of $9.6 million. Basic and diluted loss per share was $(0.02) on a weighted average 422.0 million common shares outstanding. Elite's operations incurred a $1.3 million negative cash flow for the six months ended September 30, 2013, due in large part to the cost of significantly expanded product development activities.
Subsequent to the end of the quarter, Elite executed a manufacturing and license agreement with Epic Pharma LLC, wherein Elite grants manufacturing and distribution rights to Epic in relation to the 12 approved ANDA's acquired by Elite in August 2013. Epic will have exclusive licenses to 6 of these approved ANDA's and non-exclusive licenses to the remaining 6 approved ANDA's. Pursuant to this agreement, Elite will receive various milestone payments and profit splits from sales of these products. Elite expects this agreement to begin generating revenues during the quarter ended December 31, 2013.
"In addition to launching a new product and substantially increasing our revenues, we have set in motion several initiatives that will have significant impact on Elite's future," commented Nasrat Hakim, President and CEO of Elite. "During this quarter, we acquired 12 new approved products, greatly accelerated the development of our abuse resistant technology and are on schedule for clinical trials to begin this year."
The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Monday, November 18, 2013 at 3:00 PM ET. Company executives will also conduct a question and answer session following their remarks. To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until December 2, 2013 by dialing:
Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840
The financial statements can be viewed in Elite's Quarterly Report on Form 10-Q at: http://www.elitepharma.com/sec_filings.asp.
What a Great Report and a huge CC on Monday.
http://online.wsj.com/article/PR-CO-20131114-913833.html?dsk=y
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2014
Revenues Increase by 83%, Product Development Accelerating
Conference Call Scheduled for Monday, November 18 at 3:00 PM ET
NORTHVALE, N.J., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the second quarter of fiscal year 2014 ended September 30, 2013.
Total revenues for the quarter ended September 30, 2013 were $1.2 million, an increase of 83% from the prior year. This growth is attributed to the recent launch of 3 new products, Naltrexone 50mg in the September quarter and Phentermine 15mg and 30mg capsules in the June quarter, combined with strong year-on-year growth of Elite's Phentermine 37.5mg tablets, Hydromorphone 8mg tablets and contract manufactured Methadone 10mg product lines.
Consolidated quarterly loss from operations was $0.7 million, and GAAP net income, including non-cash income related to the accounting treatment of preferred share and warrant derivatives was a net loss of $9.6 million. Basic and diluted loss per share was $(0.02) on a weighted average 422.0 million common shares outstanding. Elite's operations incurred a $1.3 million negative cash flow for the six months ended September 30, 2013, due in large part to the cost of significantly expanded product development activities.
Subsequent to the end of the quarter, Elite executed a manufacturing and license agreement with Epic Pharma LLC, wherein Elite grants manufacturing and distribution rights to Epic in relation to the 12 approved ANDA's acquired by Elite in August 2013. Epic will have exclusive licenses to 6 of these approved ANDA's and non-exclusive licenses to the remaining 6 approved ANDA's. Pursuant to this agreement, Elite will receive various milestone payments and profit splits from sales of these products. Elite expects this agreement to begin generating revenues during the quarter ended December 31, 2013.
"In addition to launching a new product and substantially increasing our revenues, we have set in motion several initiatives that will have significant impact on Elite's future," commented Nasrat Hakim, President and CEO of Elite. "During this quarter, we acquired 12 new approved products, greatly accelerated the development of our abuse resistant technology and are on schedule for clinical trials to begin this year."
The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Monday, November 18, 2013 at 3:00 PM ET. Company executives will also conduct a question and answer session following their remarks. To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until December 2, 2013 by dialing:
Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840
The financial statements can be viewed in Elite's Quarterly Report on Form 10-Q at: http://www.elitepharma.com/sec_filings.asp.
What does that mean? I am still trying to understand this. This is a most peculiar stock with high upside obviously and going to be a traders dream for awhile if that is your game.
I still find it peculiar how news for TDEY related to IPOINT TV does not show up on my trading platform. It will mention the stock symbol and the company but it doesn't hit my platform.
It would almost seem like someone does not want the company to get the publicity.
Keep your eye on short volume but it means little to me until you see well above 50% numbers. Watch the MMs too. You can begin to figure out which ones are naked shorting to cover orders. Means little really.
I am sure people are willing to short these stocks but it is probably not that common and perhaps more of an intraday thing. Risk Reward is just not there due to the cost, liquidity and risk.
Just my .02
Ok what is missing from he filings, you have my interest.
Thanks. It should be a no brainer for anyone traveling overseas. For a few bucks your family can reach you anytime for minimal cost. Think about sending your kids on an exchange program, family going over etc....
Very odd that people would continue to present misinformation after they note the conference call where they can hear what was actually said or read the transcript. Trials are be initiated and plan to submit results to FDA in 6 months for the twice a day Oxycontin product.
From the transcript from 6 weeks ago. I suspect we will get an announcement here shortly. This is just one of a bunch of items I am expecting from the company this year.
"Well, our next step is to capitalize on that, as for our clinical trials. We are initiating clinical trial within the next two to three months, okay on our twice-a-day. As I said earlier, we have already conducted a study on 19 subjects on the once-a-day and the results were phenomenal. So, we are going for the twice-a-day right now on a full subject.
And we will decide the next step after that. We are hoping as per our communication with the FDA that we will go through three stages or three things over the next six months before we finally are ready to submit our ANDA for approval."
I have an idea I want to pass on to the CEO. I may call him again, but if you guys talk to him here is something they should be considering.
The value and revenue drivers for this company is in the long distance imo. I used to travel overseas for work and calling home was always problematic.
However now with this app, people that travel for work can use their same phone (we had iphones) download the app and for minimal cost compared to what it would normally cost. We used Skype from the hotel rooms and our laptops.
He should be advertising with websites like Travelocity, Expedia, Orbitz, the Shatner one etc.....
Even could be an add on cost when you are checking out from ordering your trip.
Also sell it through travel agents. It would be an easy sell and give everyone a cut for the sales.
Give people the peace of mind that their family can reach them anytime on their trip just like they normally would without worry of the costs.
A couple notes,
Be skeptical of Finra shorting numbers. I am not saying it is naked shorting, MMs or just people shorting the stock. My experience is that most of the time it is traders selling into the bid and trying to maneuver into position and create sellers, hold the price down, frustrate longs.
I like this App and it has a lot of possibilities, just need the revenues
Anyone know why news does not shop up for SWRF on my trading platforms but it does for TDEY?
From a market cap perspective which I have preached here in the past, Elite has 20 approved drugs. 20 more in the pipeline. Any comparison to a similar company and you have to look at two companies and add them or extrapolate. Either way you end up with market caps in the 100s of millions.
However with this Epic deal, what has transpired is that Elite made themselves extremely profitable from Operations. It was a brilliant move.
Epic has a huge facility and this relationship with Mikah is not fully understood yet. These products are very valuable....much more then the 10m bucks obviously.....I am saving some of this info for later but people should dig deeper. A lot more going on then we realize.
Yeah watching the bid and ask, you can almost smell the attempts to shake people out. Reading the board today, I barely see anyone discussing the trials, outcomes, various products, all the pending transfers, pending approvals etc, patents.....
Most twelve cent stocks would have people focused squarely on these any one of these items. Kind of like poster couch noted how mgmt. said they are kind of surprised the market hasn't caught on yet...
But there are forces willing to do whatever they can to hold the price down and manipulate others. It is amazing what you can figure out watching trading and doing your DD.
Why all the focus on the run up in 2011. The company was going out of business and there were very few shares that were actually sold at .26. You can still check the charts you know?
However you can see how explosive this company and this market can be. Trials on the $2.7B market will be fun.
Do you think they will announce the CRO for these studies here shortly? Maybe let it fly on the CC.
Also since there are partners already interested, I am starting to think that there is a lot more going on for these trials then simply the sake of FDA approvals. These guys will sell this company for big bucks. That is the most likely, and logical conclusion and the reason someone like Nasrat Hakim buys 11m shares and takes over the company.
Interesting run up here. We saw how thin it was before but it got pushed down and here we are again but I don't think it is coming back down. It does seem tied to TDEY but should have a market cap of TDEY x 5 IMO.
Interesting. Almost no short volume. Usually you see some from the MMs like Knight Capital to naked short to cover trades as part of normal day to day.
So what we see here is traders working the bid and ask, steady buying and selling and typical manipulative tactics watching bid and ask....and likely a bunch of accumulation.
The Chart shows the buildup. The last run was based on the addition of 12 FDA approved drugs but this next one should be based on the announcement of the trials for Oxycontin market of $2.7B market.
However there are numerous other items that could step in like pending drug approvals and partnerships pending. Also look for an announcement for the Conference call in a couple weeks. This will be based on these trials. This will be a highly anticipated CC.
I believe in the finance world also discussed by those like the mad money guy on CNBC, Kramer, there are folks hired to try and manipulate others. Kramer has admitted as such. These folks are sometimes overseas so they can skirt the law. ELTP will attract these types because it is extremely undervalued....20 FDA approved drugs, huge R&D, financing, and these folks work to see the stock held down for accumulation, covering a short position(There isn't one here really), competition, etc...
I refer to them as fluffers for a variety of reasons.
Very exciting . Trials starting shortly. 13 more FDA approved drugs. 3 more pending approval. 3 patents.
Multiple ART products. CEO loan to limit the dilutive effect of the 10m financing and accelerate R&D efforts...ie trials about to start as noted.
Partnerships with major pharmas in negotiation.
Rizzo,
If you think about what we learned at the R&R conference and this loan, it becomes obvious that they are not taking anything less then top dollar. Getting these trials going first brings in more money. $1m now, gets you $50m more later.m Remember the value accretion curve.? Good times.
Nasrat has noted the superiority, simplicity of the tech and lets not forget he was involved in other competing techs at Actavis and Alpharma. He came to Elite with a purpose, and a pocketful of shares.
The science here is straightforward as the Chairman likes to say and it is the same concept as Embeda and ALO-02 but far more robust and modular.
Interesting day. Ipoint App should be released here shortly. The CC was a good listen. Good volume today. Looked like the continued shake out. Again, If TDEY is a 1m cap, SWRF should be 5m cap in my opinion anyway.
Did some review of the App online. Lots of Christian channels and international stuff. It is interesting. I like what they are trying to do and finally understanding the concept of going after content.
The PRs are weird though. No real discussion here over this recent one. WOnder what was said at the meetings. Is todays action further shake out. And if TDEY is hot, and its content will be on SWRFs Ipoint, then this should be much much higher but maybe its all a sham but I haven't figured out how yet.
iPoint TV Enters Into Talks with Major Broadcast Networks and TV Stations to Retransmit on its TV Everywhere
http://www.eteligis.com/ViewSubmission.aspx?submissionRequest=23055
Poorme, it is pretty much accepted that these type products will be fast tracked at this point. Between societal need, congress and politics, that is trend on these endeavors right now. This point really can't be argued if you take 5 minutes and review the market right now.
Actually his treasury is not enhanced with anything until the money is loaned and held as loan. It is a revolving line of credit and unsecured at that.
Every loan comes with an interest rate.
Are you accusing the CEO of some sort of malfeasance? It was approved by the BOD who are the biggest share holders in the company alongside that same CEO who is obviously incredibly wealthy already.
Today's move was brilliant for the company and shareholders.
How many CEOs do you see giving unsecured loans out when dilutive financing is available?
Let me ask you a question
Find drug companies that have ~40 products in their pipeline
Of the 40, 20 are approved already and many have very limited competition
Trial about to begin for which they have partnered interest from major pharmas and the products and in a market worth over 3 billions dollars again with limited competition
Add in a CEO with incredible experience, knowledge and his own money in the game
You will be looking at companies with 200-300 million dollar market caps.
Do you agree?
Curious, I am watching TDEY, have a little SWRF, watching closely. Did anyone here attend the meet and greet last night?